Zai Lab Ltd Ordinary Shares 09688
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 12.64
- Day Range
- HKD 12.40–12.86
- 52-Week Range
- HKD 10.56–29.50
- Bid/Ask
- HKD 12.62 / HKD 12.64
- Market Cap
- HKD 12.52 Bil
- Volume/Avg
- 2.6 Mil / 4.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.73
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 2,175
- Website
- https://www.zailaboratory.com
Comparables
Valuation
|
Metric
|
09688
|
APLM
|
02105
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.93 | 2.35 | 2.72 |
Price/Sales | 5.73 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
09688
|
APLM
|
02105
|
|---|---|---|---|
Quick Ratio | 4.29 | 2.82 | 9.91 |
Current Ratio | 4.63 | 2.95 | 9.98 |
Interest Coverage | — | −1,154.63 | −447.63 |
Quick Ratio
09688
APLM
02105
Profitability
|
Metric
|
09688
|
APLM
|
02105
|
|---|---|---|---|
Return on Assets (Normalized) | −22.36% | −123.31% | −48.47% |
Return on Equity (Normalized) | −26.78% | — | — |
Return on Invested Capital (Normalized) | −30.45% | — | — |
Return on Assets
09688
APLM
02105
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tnpqyklk | Vhlgf | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tsdmhbxy | Jjvhzmh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yssywcjbh | Zsgbyf | $97.8 Bil | |
MRNA
| Moderna Inc | Njpmfgf | Zkkr | $41.3 Bil | |
ARGX
| argenx SE ADR | Zvttrznbd | Jdzf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wvfcvfsh | Dbx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dqfvgvrk | Xythdl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xspfkgqv | Lfwthf | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hytnhfnv | Ymrjxk | $12.5 Bil | |
INCY
| Incyte Corp | Tgmcqgp | Wxscqq | $11.6 Bil |